Status:
COMPLETED
Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The primary objective is to assess the safety and tolerability of a single oral dose of BMS-708163 in healthy young male subjects and in elderly male and female subjects.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Panels 1- 8 and Panels 14-15: healthy male subjects between the ages of 18 to 45
- Panels 9 and 10: healthy elderly males and females ages 60 and greater
- Panel 11: healthy males between the ages of 46-59
- Panel 12: males and/or females either healthy or with mild cognitive impairment (MCI) between the ages of 60 and 74
- Panel 13: males and/or females, healthy or with Alzheimer's disease (AD) or MCI that were 75 years of age or greater
- Acceptable medical history, physical examinations, vital signs, electrocardiograms, hemoccult stool tests, and clinical laboratory evaluations
Exclusion
Key Trial Info
Start Date :
June 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
116 Patients enrolled
Trial Details
Trial ID
NCT01454115
Start Date
June 1 2007
End Date
March 1 2009
Last Update
November 21 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.